Vanguard Group’s Antares Pharma, Inc. ATRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-8,643,155
| Closed | -$35.4M | – | 4669 |
|
|
2022
Q1 | $35.4M | Buy |
8,643,155
+194,168
| +2% | +$704K | ﹤0.01% | 2477 |
|
|
2021
Q4 | $30.2M | Sell |
8,448,987
-159,671
| -2% | -$558K | ﹤0.01% | 2630 |
|
|
2021
Q3 | $31.3M | Buy |
8,608,658
+346,498
| +4% | +$1.4M | ﹤0.01% | 2623 |
|
|
2021
Q2 | $36M | Sell |
8,262,160
-32,656
| -0.4% | -$133K | ﹤0.01% | 2541 |
|
|
2021
Q1 | $34.1M | Buy |
8,294,816
+187,261
| +2% | +$811K | ﹤0.01% | 2515 |
|
|
2020
Q4 | $32.3M | Buy |
8,107,555
+153,847
| +2% | +$498K | ﹤0.01% | 2407 |
|
|
2020
Q3 | $21.5M | Sell |
7,953,708
-116,196
| -1% | -$322K | ﹤0.01% | 2420 |
|
|
2020
Q2 | $22.2M | Buy |
8,069,904
+167,927
| +2% | +$469K | ﹤0.01% | 2371 |
|
|
2020
Q1 | $18.6M | Buy |
7,901,977
+11,969
| +0.2% | +$40.7K | ﹤0.01% | 2319 |
|
|
2019
Q4 | $37.1M | Buy |
7,890,008
+24,718
| +0.3% | +$101K | ﹤0.01% | 2242 |
|
|
2019
Q3 | $26.3M | Buy |
7,865,290
+446,253
| +6% | +$1.47M | ﹤0.01% | 2345 |
|
|
2019
Q2 | $24.4M | Buy |
7,419,037
+110,433
| +2% | +$319K | ﹤0.01% | 2418 |
|
|
2019
Q1 | $22.1M | Buy |
7,308,604
+254,223
| +4% | +$824K | ﹤0.01% | 2457 |
|
|
2018
Q4 | $19.2M | Buy |
7,054,381
+566,916
| +9% | +$1.87M | ﹤0.01% | 2459 |
|
|
2018
Q3 | $21.8M | Buy |
6,487,465
+84,181
| +1% | +$260K | ﹤0.01% | 2540 |
|
|
2018
Q2 | $16.5M | Buy |
6,403,284
+165,382
| +3% | +$412K | ﹤0.01% | 2651 |
|
|
2018
Q1 | $13.7M | Buy |
6,237,902
+170,863
| +3% | +$385K | ﹤0.01% | 2658 |
|
|
2017
Q4 | $12.1M | Sell |
6,067,039
-80,172
| -1% | -$174K | ﹤0.01% | 2731 |
|
|
2017
Q3 | $19.9M | Sell |
6,147,211
-39,021
| -0.6% | -$120K | ﹤0.01% | 2489 |
|
|
2017
Q2 | $19.9M | Buy |
6,186,232
+567,144
| +10% | +$1.61M | ﹤0.01% | 2459 |
|
|
2017
Q1 | $16M | Buy |
5,619,088
+232,349
| +4% | +$559K | ﹤0.01% | 2540 |
|
|
2016
Q4 | $12.6M | Sell |
5,386,739
-14,501
| -0.3% | -$27.6K | ﹤0.01% | 2638 |
|
|
2016
Q3 | $9.07M | Buy |
5,401,240
+298,282
| +6% | +$365K | ﹤0.01% | 2735 |
|
|
2016
Q2 | $5.36M | Sell |
5,102,958
-321,207
| -6% | -$310K | ﹤0.01% | 2946 |
|
|
2016
Q1 | $4.72M | Buy |
5,424,165
+174,837
| +3% | +$169K | ﹤0.01% | 2983 |
|
|
2015
Q4 | $6.35M | Buy |
5,249,328
+138,655
| +3% | +$193K | ﹤0.01% | 2878 |
|
|
2015
Q3 | $8.69M | Buy |
5,110,673
+427,705
| +9% | +$838K | ﹤0.01% | 2679 |
|
|
2015
Q2 | $9.74M | Buy |
4,682,968
+426,536
| +10% | +$1.03M | ﹤0.01% | 2683 |
|
|
2015
Q1 | $11.5M | Buy |
4,256,432
+296,670
| +7% | +$753K | ﹤0.01% | 2575 |
|
|
2014
Q4 | $10.2M | Buy |
3,959,762
+177,715
| +5% | +$399K | ﹤0.01% | 2528 |
|
|
2014
Q3 | $6.92M | Sell |
3,782,047
-93,703
| -2% | -$204K | ﹤0.01% | 2668 |
|
|
2014
Q2 | $10.3M | Buy |
3,875,750
+105,274
| +3% | +$317K | ﹤0.01% | 2488 |
|
|
2014
Q1 | $13.2M | Buy |
3,770,476
+210,617
| +6% | +$934K | ﹤0.01% | 2362 |
|
|
2013
Q4 | $15.9M | Buy |
3,559,859
+156,972
| +5% | +$640K | ﹤0.01% | 2249 |
|
|
2013
Q3 | $13.8M | Buy |
3,402,887
+63,081
| +2% | +$276K | ﹤0.01% | 2245 |
|
|
2013
Q2 | $13.9M | Buy |
+3,339,806
| New | +$12.9M | ﹤0.01% | 2199 |
|
Other funds holding ATRS
Vanguard Group's ATRS Position: Q2 2022 in Review
Vanguard Group sold out of Antares Pharma, Inc. (ATRS) in Q2 2022, closing a stake of 8,643,155 shares — an estimated $35.4M sold.
Vanguard Group first reported a position in ATRS in Q2 2013 and held it in 36 quarters. The position peaked at $37.1M in Q4 2019. 1 fund tracked by Wall St. Rank holds ATRS as of Q2 2022.
- Vanguard Group reported no remaining Antares Pharma, Inc. position as of Q2 2022 after selling out during the quarter.
- Vanguard Group sold 8,643,155 Antares Pharma, Inc. shares in Q2 2022, an estimated $35.4M.
- Vanguard Group first reported a position in Antares Pharma, Inc. in Q2 2013 and held it in 36 quarters.
- Vanguard Group's Antares Pharma, Inc. position peaked at $37.1M in Q4 2019.
- 1 fund tracked by Wall St. Rank held Antares Pharma, Inc. as of Q2 2022.
Based on Vanguard Group's 13F filing for Q2 2022, filed 12 Aug 2022.